All In Biotech

Drug Trial Radar · NCT02760433

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

368

Actual

Start

Jan 25, 2017

Primary completion

Sep 12, 2019

Study completion Oct 1, 2019

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
Quintiles, Inc.; OCT Clinical Trials; Mene Research
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • OlokizumabDrug

    160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

  • PlaceboDrug

    sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) ResponseTime frame: at Week 12

Locations

116 sites in 11 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • CHI St. Vincent Hot Springs

    Hot Springs, Arkansas

  • Medvin Clinical Research

    Covina, California

  • TriWest Research Associates, LLC

    El Cajon, California

  • Saint Jude Heritage Medical Grp

    Fullerton, California

  • С V Mehta MD Med Corp.

    Hemet, California

  • Advanced Medical Research, LLC

    Lakewood, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Riverside Medical Clinic

    Riverside, California

  • East Bay Rheumatology Medical Group, Inc.

    San Leandro, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • Denver Arthritis Clinic

    Denver, Colorado

  • Javed Rheumatology Associates

    Newark, Delaware

  • RASF - Clinical Research Center

    Boca Raton, Florida

  • Suncoast Research Group LLC

    Miami, Florida

  • Omega Research Consultants

    Orlando, Florida

  • Family Clinical Trials, LLC.

    Pembroke Pines, Florida

  • AdventHealth Medical Group, PA

    Tampa, Florida

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • University of Kansas Hospital

    Kansas City, Kansas

  • Graves Gilbert Clinic

    Bowling Green, Kentucky

  • The Arthritis & Diabetes Clinic, Inc.

    Monroe, Louisiana

  • Klein and Associates, M.D., P.A.

    Hagerstown, Maryland

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • Glacier View Research Instutute-Rheumatology

    Kalispell, Montana

  • Arthritis & Osteoporosis Associates, PA

    Freehold, New Jersey

  • Lovelace Scientific Resources, Inc.

    Albuquerque, New Mexico

  • NYU Langone Ambulatory Care

    New York, New York

  • Medication Management, LLC

    Greensboro, North Carolina

  • Cape Fear Arthritis Care

    Leland, North Carolina

  • Carolina Arthritis Associates

    Wilmington, North Carolina

  • Trinity Medical Group

    Minot, North Dakota

  • Cincinnati Rheumatic Disease Study Group

    Cincinnati, Ohio

  • STAT Research, Inc.

    Dayton, Ohio

  • Clinical Research Source, Inc.

    Perrysburg, Ohio

  • Arthritis Group

    Philadelphia, Pennsylvania

  • Low Country Research Center

    Charleston, South Carolina

  • Amarillo Center for Clinical Research

    Amarillo, Texas

  • Austin Regional Clinic, P.A.

    Austin, Texas

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.